Karachi: In a landmark meeting held on February 6, 2025, the Board of Directors of Citi Pharma Limited convened at their Head Office and approved several strategic initiatives aimed at expanding their pharmaceutical capabilities and exploring new business ventures. The decisions made reflect the company's commitment to innovation and growth in the pharmaceutical sector.
During the meeting, the Board confirmed the minutes from their previous meeting held on October 29, 2024, establishing a continuity of governance and decision-making. Among the notable approvals was the establishment of a biological section and plant dedicated to producing various types of Insulin, including Regular Insulin, Glargine, Lispro, As part, Detemir, and Delude, as well as GLP-1, including Similitude and Bio-similar. This moves underscores Citi Pharma's commitment to bolstering its portfolio in the diabetic care market.
The Board also sanctioned the development of a Carbapenems section and plant, focusing on antibiotics like Hopene, Meropenem, Dorine, and Ertapenem. This decision aligns with the company's strategy to enhance its capabilities in producing high-demand antibiotic formulations. Approval was also granted for the establishment of an Antibiotic plant for the formulation section, further strengthening Citi Pharma's position in the market.
Another significant decision was the formation of Citi REIT Management Company as a wholly-owned subsidiary. This move is part of Citi Pharma's broader strategy to diversify its business model by entering the real estate market through fund raising for various projects. Additionally, the Board greenlighted discussions for a joint venture with international partners to develop a hospital, marking Citi Pharma's foray into healthcare services.
According to information available from the Pakistan Stock Exchange (PSX), these initiatives are expected to significantly impact the designated market category of Citi Pharma Limited, positioning the company for substantial growth and increased shareholder value. The Board also reviewed matters under consideration, including discussions on ESG regulatory expectations and the formation of relevant committees. Moreover, it was decided to utilize proceeds from the hospital's Initial Public Offering (IPO) for establishing the approved pharmaceutical projects.
Citi Pharma Limited's strategic decisions reflect its aggressive approach to expanding its operational capabilities and exploring new business avenues, ensuring its leadership position in the pharmaceutical industry. The Board has instructed the TRE Certificate Holders of the Exchange to be informed accordingly.